none 10.31254/phyto.2026.15207 BioMed Research Publishers BioMed Research Publishers 16195 194022389 316921 20260428131321781 10.31254 2026-04-28T13:13:29Z 2026-04-28T13:13:28Z 0 The Journal of Phytopharmacology J Phytopharmacol 2320480X 10.31254/phyto https://phytopharmajournal.com/ 04 27 2026 15 2 Chenthamarai Selvi Ganesan Assistant Professor, Department of Toxicology, Govt. Siddha Medical College, Palayamkottai, Tirunelveli - 627002, Tamil Nadu, India https://orcid.org/0009-0001-8253-3315 Shanmugam Muthu PG Scholar, Department of Toxicology, Govt. Siddha Medical College, Palayamkottai, Tirunelveli - 627002, Tamil Nadu, India https://orcid.org/0009-0001-6184-9759 Background: Snakebite envenomation remains a neglected tropical disease with significant global morbidity. Phospholipase A₂ (PLA₂) is a venom enzyme that causes inflammation, tissue destruction and myonecrosis. Siddha medicinal plants offer promising phytochemical compounds for novel antivenom therapeutics. Objective: To evaluate selected phytochemicals from Siddha medicinal plants as potential inhibitors of snake venom phospholipase A₂ using drug-likeness screening, ADMET profiling, and molecular docking approaches. Methods: Nine phytocompounds from Siddha herbs, Indigotin, Aristolochic acid, Lucidenic acid, Esculetin, Leucasperoside B, Friedelin, Rutin, Quercetin, and Beta-sitosterol, were evaluated through drug-likeness screening (Lipinski's Ro5, Ghose, Veber, Egan rules), in silico ADMET profiling (SwissADME, pkCSM), and molecular docking against PLA₂ (PDB: 2QOG) using AutoDock 4.2. Results: Binding affinities ranged from -5.62 kcal/mol (Indigotin) to -12.73 kcal/mol (Rutin). Rutin showed the strongest binding, while Quercetin and Lucidenic acid exhibited the best balance of drug-likeness, ADMET properties, and catalytic site engagement (Asp49, Tyr52). Seven compounds directly interacted with core catalytic residues. Conclusion: This first systematic in silico study of Siddha phytocompounds against snake venom PLA₂ identifies Quercetin and Lucidenic acid as priority lead candidates, providing computational rationale for traditional antivenom use and a foundation for future experimental validation. 04 27 2026 164 175 1 10.31254/biomed-crossmark-policy www.biomedresearch.org false 10.31254/phyto.2026.15207 https://phytopharmajournal.com/articles/abstracts/898/year=2026&vol=15&issue=2